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Abstract
The epithelial-to-mesenchymal transition (EMT) that occurs during embryonic development is recapitulated during
tumor metastasis. Important regulators of this process include growth factors, transcription factors, and adhesion
molecules. New evidence suggests that microRNA (miRNA) activity contributes tometastatic progression and EMT;
however, the mechanisms leading to altered miRNA expression during cancer progression remain poorly under-
stood. Importantly, overexpression of the epidermal growth factor receptor (EGFR) in ovarian cancer correlates with
poor disease outcome and induces EMT in ovarian cancer cells.We report that EGFR signaling leads to transcriptional
repression of the miRNA miR-125a through the ETS family transcription factor PEA3. Overexpression of miR-125a
induces conversionof highly invasive ovariancancer cells fromamesenchymal to anepithelialmorphology, suggesting
miR-125a is a negative regulator of EMT. We identify AT-rich interactive domain 3B (ARID3B) as a target of miR-125a
and demonstrate that ARID3B is overexpressed in human ovarian cancer. Repression of miR-125a through growth
factor signaling represents a novel mechanism for regulating ovarian cancer invasive behavior.
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Introduction
MicroRNA (miRNA) are a novel class of noncoding regulatory RNA
molecules. They regulate gene expression by associating with the 3′un-
translated region (3′UTR) of mRNA. Every tumor type surveyed thus
far expresses different miRNA than the corresponding normal tissue,
and multiple reports indicate that miRNA are differentially expressed
in ovarian cancer [1,2]. These findings suggest that miRNAmay be in-
volved in tumor initiation, growth, or progression; however, the mech-
anisms leading to regulation of miRNA expression in ovarian cancer
have not been characterized.
The epidermal growth factor receptor (EGFR) is often mutated or
overexpressed in ovarian cancer [3–8], and expression correlates with
poor survival. One of the ways that EGFR is thought to promote tu-
mor progression is by induction of the epithelial-to-mesenchymal
transition (EMT). Loss of E-cadherin is a critical step in EMT [9].
EGFR induces loss of E-cadherin in ovarian tumor cells, and EGFR
expression correlates with E-cadherin loss in ovarian tumors [10]. Ac-
tivation of EGFR also drives ovarian cancer cell invasion and activation
of matrix metalloproteinases [10–13]. Therefore, multiple signaling
pathways and gene products that contribute to cancer progression are
EGF-regulated.
InDrosophila, EGFR induces transcription of miR-7 during photo-
receptor differentiation through degradation of the ETS family tran-
scription factor YAN [14]. Because EGFR-mediated signaling events
are conserved between Drosophila and humans, we hypothesized that
EGFRmay regulate miRNA in human disease. Because YANnegatively
regulated miRNA gene expression, we chose to identify miRNA with
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reduced expression in ovarian cancer. Two separate studies reported that
miR-125a was decreased in ovarian cancer, so we focused on EGFR reg-
ulation of miR-125a [1,2].
In this study, we examined the expression of miR-125a in response
to EGF treatment and showed for the first time in mammalian cells
that EGF regulated miRNA expression at the transcriptional level
through the ETS factor PEA3. Because miR-125a expression induced
amesenchymal-to-epithelial transition in invasive ovarian cancer cells, we
chose to identify targets of miR-125a that may regulate EMT. AT-rich
interactive domain 3B (ARID3B) seemed to be a strong target by se-
quence alignment. ARID3B transforms fibroblasts (withMYCN) and is
tumor-promoting in neuroblastoma cells [15]. Interestingly, ARID3B is
essential for the development of mesenchymal cells in embryos and loss
of ARID3B is embryonic lethal [16]. These studies imply that ARID3B
may play an important role in EMTand tumor progression. Our find-
ings demonstrate that miR-125a regulates ARID3B expression and that
ARID3B is elevated in ovarian cancer.
Materials and Methods
Cell Culture
The ovarian carcinoma cell lines OVCA433 and DOV13 (and stable
cell lines) were grown in minimum essential medium supplemented with
10% FBS, 0.2 mM L-glutamine, 1 mM sodium pyruvate, 50 U/ml
penicillin, and 50 μg/ml streptomycin. OVCA433 cells expressing
PEA3 were described previously [11]. To generate miR-125a expressing
cell lines, pre-miR-125a was cloned into pSilencer (Ambion, Austin,
TX), and OVCA433 and DOV13 cells were transfected according to
the instructions using Superfect (Qiagen, Valencia, CA). Stable cell lines
were maintained in either 1 mg/ml G418 or 200 μg/ml Hygromycin B
(Invitrogen, Carlsbad, CA). Epidermal growth factor was purchased
from Biomedical Technologies, Inc (Stoughton, MA).
Western Blots
Cells were lysed in RIPA buffer (50 mM Tris pH 7.5, 150 mM
NaCl, 1% Triton X-100, 5 mM EDTA). Protein concentration was
determined using the BCA kit (Pierce, Rockford, IL). Twenty-five
micrograms of protein was separated by SDS-PAGE and transferred
to nitrocellulose. Blots were probed with the following antibodies:
E-cadherin, N-cadherin, and β-catenin from BD Transduction Labo-
ratories (San Jose, CA); GAPDH from Chemicon (Temecula, CA);
and ARID3B from Abcam (Cambridge, MA). Antibodies for Snail
and β-tubulin were from Santa Cruz Biotechnologies (Santa Cruz,
CA). Densitometry was performed using the Kodak Image Station
using Molecular Imaging Software version 4.0 (Carestream Health,
New Haven, CT). Statistics were calculated using Student’s t test.
Microscopy
Phase-contrast imaging and immunofluorescence microscopy were
performed using an Olympus BH-2 inverted microscope or an Olym-
pus 1X70 fluorescence microscope (Olympus, Center Valley, PA), re-
spectively. For immunofluorescence studies cells were fixed in ice-cold
acetone, blockedwithBSA, andwere then incubatedwith anti-ARID3B
(Abcam), anti–E-cadherin, anti–N-cadherin, or anti–β-catenin (all from
BD Transduction Laboratories). Fluorescein isothiocyanate–conjugated
antirabbit or antimouse secondary antibodies from Chemicon were
used. Coverslips were mounted using Vectashield mounting medium
with 4′,6-diamidino-2-phenylindole (Vector Laboratories, Burlingame,
CA). Bright field (for immunohistochemistry [IHC]) images were col-
lected on a Zeiss Axioskop2 MOT (Carl Zeiss Micro Imaging, Inc,
Thornwood, NY) using Slidebook software (Olympus).
Immunohistochemistry
IHC was performed on US Biomax, Inc (Rockville, MD) tissue ar-
rays (OV807, OV1001, OV808) for ARID3B. IHC was performed
according to the staining procedure for paraffin sections provided by
the VECTASTAIN ABC KITusing DAB as a substrate solution and
Hematoxylin QS as a counterstain (all from Vector Laboratories).
RNA Detection
Total RNAwas extracted with TRIzol (Invitrogen) according to the
manufacturer’s instructions. Complementary DNA (cDNA) was gen-
erated from 1 μg of RNA using High Capacity cDNA Archive Kit or
5 ng of RNA using a miRNA kit according to the manufacturer’s in-
structions (Applied Biosciences, Foster City, CA). For quantitative
PCR (Q-PCR) SYBR Master Mix and TaqMan Master Mix solution
was obtained from Applied Biosciences, and primer/probe QuantiTect
Primer Assays for GAPDH and ARID3B were obtained from Qiagen
and miR-125a Primer Assays were included in the miRNA cDNA kit.
All reactions were performed in duplicate, and all experiments per-
formed at least three times using a 7900HTsequence detection system
(Applied Biosciences). ΔΔCT calculations were used to normalize sig-
nal versus a GAPDH control. Statistics were calculated using Student’s
t test. Reverse transcription–polymerase chain reaction (RT-PCR) for pri-
miR-125a and 18s RNAwas performed using the following primers:
Pri-F, 5′-GGGTTCCTTGGGGAGGAG-3′ and Pri-R, 5′-ATTCC-
CCAGGTGTGTGGTT-3′; 18sF, 5′-AAACGGCTACCACATC-
CAAG-3′ and 18sR, 5′-CCTCCAATGGATCCTCGTTA-3′.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed as described
previously [11]. PCR was performed on the miR-125a promoter using
the following primers: 5′-GGGTAGGTAGGAAGCAGGTG-3′ and
5′-CAAGGAACCCAGGAGTCCA-3′. Immunoprecipitation (IP)
with anti–β-tubulin (Santa Cruz Biotechnologies) was used as a negative
control. ChIP controls were also performed on samples without chro-
matin or without antibody. As an additional negative control, we per-
formed ChIP to a region upstream of the miR-125a promoter using
the following primers: 5′-CTTAGGTCCGGGGAATCTCT-3′ and
5′-GGGTCTACGGCCAGCTCT-3′.
Statistical Analysis
Statistical analysis for immunohistochemistry was performed using
a Jonckheere-Terpstra exact test for trend was used to compare the dis-
tribution of expression levels (high, medium, low, none) across tissue
types (serous tumor, benign tumor, normal epithelium) followed by
pairwise comparisons of tissue types. A Bonferroni adjustment was
applied to the P values for the pairwise comparisons. All tests were
two-sided.
Results
EGF and PEA3 Regulate miR-125a Expression
To identify miRNA down-modulated in ovarian cancer, we com-
pared the published reports from Nam et al. [2] and Iorio et al. [1].
The only miRNA that were decreased in both reports were members
of either the miR-125a/b family or the miR-99a/b100 family. Anal-
ysis of the genomic regions of DNA 1000 bp upstream of miR-125a,
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miR-125b, miR-99a, and miR-100 (data not shown) revealed that
miR-125a contained five PEA3 binding sites, making it a candidate for
EGFregulation [11].miR-100 had one PEA3 site in the upstream region,
whereas miR-99a and miR-125a had no binding sites (data not shown).
Therefore, we chose to focus our studies on miR-125a regulation.
For the studies presented here, we used two different cell lines. The
ovarian cancer cell line OVCA433 exhibits an epithelial morphology
and is poorly invasive. Importantly, OVCA433 cells respond robustly
to EGF treatment by undergoing an EMT and becoming invasive
[10,11,17]. DOV13 cells will also be used because they are highly in-
vasive ovarian tumor cells. We have shown that EGFR stimulates the
activity of the transcription factor PEA3 [11]. To determine whether
PEA3 repressesmiR-125a, we performedRT-PCR for the pri-miR-125a
(the original miRNA transcript that has not undergone processing) on
vector control (V3) and PEA3 overexpressing (P2) cells (which were
characterized in the study of Cowden Dahl et al. [11] and derived from
the OVCA433 cells). Pri-miR-125a expression was reduced in PEA3
overexpressing cells (Figure 1A), and similarly, 20 nM EGF treatment
for 8 hours also reduced transcription of miR-125a (Figure 1A).We next
assessed if the mature miR-125a was reduced as a result of EGFR and
PEA3 activation. miR-125a expression was decreased by 40% (P < .05)
and 50% (P < .05) by EGF treatment or PEA3 overexpression, respec-
tively (Figure 1B).We observed a 20%decrease inmiR-125a inDOV13
cells and immortalized ovarian epithelial cells (IOSE 398; data not
shown). We predict that the smaller change in miR-125a expression
in response to EGF in DOV13 cells results from the cells being less re-
sponsive to EGF stimulation. EGF stimulates OVCA433 invasion by
12-fold [11] and DOV13 invasion by only 2-fold [13]. Interestingly,
the total PEA3 protein expression is similar between DOV13 and
OVCA433 cells and is provided in Figure W1.We find that EGFR sig-
naling and PEA3 activity repress transcription of miR-125a leading to
decreased mature miR-125a.
We next examined if miR-125a repression occurs through the EGF-
regulated transcription factor PEA3. ChIP demonstrated that treat-
ment of cells with 20 nM EGF enhanced PEA3 association with the
miR-125a promoter (Figure 1C ) indicating that EGFR activation of
PEA3 represses miR-125a transcription. Of note, we see PEA3 associ-
ates with the miR-125a promoter after 2 hours of EGF treatment fol-
lowed by the decrease in mature miR-125a between 4 and 8 hours
(data not shown and Figure 1B). We predict that PEA3 associates with
the miR-125a promoter within 2 hours of EGF treatment, but the de-
crease in total miR-125a expression is evident once the existing pool of
mature miR-125a is degraded. As controls, we performed ChIP for a
region of DNA upstream of the miR-125a promoter. This work repre-
sents the first example of EGF leading to transcriptional regulation of
a miRNA in human cancer cells.
Overexpression of miR-125a Results in a Mesenchymal-to-
Epithelial Transition
Because EGFR activity represses miR-125a, we generatedOVCA433
and DOV13 cells that overexpress miR-125a (433mir125a and DOV-
mir125a, respectively). These cell lines enable us to investigate a
Figure 1. EGFR signaling through PEA3 represses miR-125a expression. (A) RT-PCR for pri-miR-125a (lanes 2-5) and 18s RNA (lanes 6-9)
on vector (V3), PEA3 (P2), OVCA433 untreated (0), and OVCA433 + 8 hours of EGF treatment (8). (B) TaqMan PCR for mature miR-125a on
untreated OVCA433 cells or treated with EGF for 8 hours and in V3 and P2 cells. Expression was normalized to untreated OVCA433 and V3
cells, respectively. *P < .05. (C) ChIP for PEA3 association with the PEA3 binding sites immediately upstream of miR-125a in V3 and P2
cells. ChIP was also performed on OVCA433 cells untreated or treated with EGF for 2 or 8 hours. IP with anti–β-tubulin was used as a
negative control. ChIP performed in the absence of chromatin (ch) or antibody (ab) did not result in PCR products. Input chromatin for
each sample is shown. ChIP was also performed on chromosomal DNA upstream of the miR-125a promoter on samples and input DNA.
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functional role for this miR-125a in cell types with different invasive
potential. OVCA433 cells normally exhibit an epithelial phenotype,
whereas DOV13 cells have a mesenchymal phenotype (Figure 2A).
Mature miR-125a was increased 2.5-fold in the 433mir125a and
Dov13mir125a clones (data not shown). Overexpression of miR-
125a does not alter the morphology of the epithelial OVCA433 cells
(Figure 2A). The 433mir125a cells appear identical to the parental
cells and express E-cadherin and junctional β-catenin, and N-cadherin
is not detectable (FigureW2). However, forced expression of miR-125a
in DOV13 cells drives the cells toward an epithelial morphology (Fig-
ure 2A), suggesting that miR-125a targets are important in the acquisi-
tion or maintenance of the mesenchymal morphology.
OVCA433 cells have junctional E-cadherin, which is typical of epi-
thelial cells, and DOV13 and DOVmir125a cells do not express junc-
tional E-cadherin but instead express N-cadherin (Figure 2, B–D).
These data suggest that E-cadherin is epigenetically silenced or actively
repressed inDOV13 cells and introduction ofmiR-125a does not reverse
the gene silencing. In support of this theory, we find that Snail expression
is slightly reduced (by approximately 15%) in the DOVmir125a cells
(Figure 2, C and D), but we do not find a concomitant increase in
E-cadherin. Others have demonstrated that restoration of E-cadherin
to junctions after EMT requires inhibition of MAP kinase signaling
and increased E-cadherin expression in cells that overexpress RAS [18].
Interestingly, DOV13 cells naturally express activated RAS [19], suggest-
ing that multiple events would need to occur simultaneously to restore
E-cadherin at junctions. Instead, elevated miR-125a in DOVmir125a
cells resulted in the distribution of N-cadherin to junctional complexes
and localization of β-catenin to cell-cell junctions (Figure 2B). These
Figure 2. miR-125a overexpression induces a mesenchymal-to-epithelial transition. (A) Phase-contrast images were collected for
OVCA433 andDOV13 cells stably transfectedwithmiR-125a (433mir125a andDOVmir125a). Originalmagnification, ×20. (B) Immunofluo-
rescence was performed on OVCA433, DOV13, and DOVmir125a cells for E-cadherin, N-cadherin, and β-catenin (in green). Nuclei are
stained with DAPI. Original magnification, ×63. (C) Western blot for E-cadherin, N-cadherin, β-catenin, and GAPDH on OVCA433,
DOV13, and DOVmir125a cells. Western blot for Snail and GAPDH on DOV13 and DOVmir125a cells. (D) Densitometry on Western blots
from panel C. #P> .05 for OVCA433 cells comparedwith DOV13 or DOVmir125a cells. *P> .05DOV13 cells comparedwith DOVmir125a.
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staining patterns indicate that in cells overexpressing miR-125a epithelial-
like adherens junctions are formedwithN-cadherin in place of E-cadherin.
Therefore, miR-125a expression represses the mesenchymal phenotype.
ARID3B Is a Target of miR-125a Repression
To identify targets of miR-125a that are important in mesenchymal
morphology, we used the online algorithm TargetScan. The 3′UTR of
ARID3B has three conserved miR-125a sites (Figure 3A). ARID3B
null mice die during midgestation with multiple defects including fail-
ure to maintain cranial mesenchyme [16]. Because ARID3B is critically
important for mesenchymal developmental during embryogenesis, we
hypothesized that ARID3B also promotes mesenchymal morphologies
or behaviors in cancer. First to assess if miR-125a regulates endogenous
ARID3B expression, we performedWestern blot analysis on whole-cell
Figure 3. miR-125a targets ARID3B for repression. (A) Alignment of human miR-125a with the three conserved sites in the ARID3B
3′UTR. (B) Western blot for ARID3B and β-tubulin on OVCA433, 433mir125a, DOV13 and DOVmir125a cells. The average percent de-
crease in ARID3B protein (for three experiments) is indicated. (C) Immunofluorescence for ARID3B (in green) and DAPI was performed
on OVCA433, DOV13, and DOVmir125a cells. Original magnification, ×63. (D) Q-PCR for ARID3B on OVCA433 cells that are untreated or
treated with 20 nM EGF for 8 hours. *P > .05.
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lysates from miR-125a overexpressing and parental cell lines. ARID3B is
expressed inOVCA433 andDOV13 cells (Figure 3,C andD). However,
in 433mir125a and DOVmir125a cells, there is approximately a 70% to
80% decrease in total ARID3B expression (Figure 3B). We confirmed
that ARID3B expression was greatly diminished in DOVmir125a cells
by immunofluorescence (Figure 3C), indicating that ARID3B is a likely
target. BecausemiR-125a is anEGF-regulatedmicroRNA,we investigated
ARID3B regulation by EGFR. By Q-PCR, we find that ARID3B expres-
sion is induced by 1.6-fold in response to EGF (P = .0398; Fig-
ure 3D). Our data imply that ARID3B may be an important mediator
of mesenchymal morphology in response to growth factor signaling.
ARID3B Is Overexpressed in Ovarian Cancer
The function of ARID3B is unknown, but its role in development
and its ability to promote tumorigenesis suggests that ARID3B may
have an important role in tumor progression [15,16]. Furthermore,
Figure 4. ARID3B expression is elevated in ovarian cancer. (A) Immunohistochemistry for ARID3B in normal ovary (a), benign ovarian
tumor (b), and two example of malignant ovarian tumors one with low staining (c) and one with high staining (d). Original magnification,
×40. Pathologic diagnosis is indicated. Arrow in panel (a) marks ovarian epithelium. Arrowheads in b to d denote brown ARID3B staining.
(B) Summary of ARID3B expression in normal ovarian epithelium, benign ovarian lesions, and serous ovarian malignant tumors. (−) = no
staining, (+) = low, (++) = moderate, (+++) = high. Staining was only scored for normal and tumor epithelia (not stroma).
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because PEA3 is overexpressed in ovarian cancer and miR-125a is de-
creased, we predict that ARID3B will be elevated in ovarian tumors
[20,21]. Ovarian cancer tissue arrays were probed for ARID3B protein
expression by IHC. Using a combination of US Biomax tissue arrays,
62 serous ovarian tumors, 17 benign ovarian tumors, and 13 normal
ovarian epithelia sections were evaluated for ARID3B staining. Exam-
ples of a typical normal ovarian epithelium, a benign borderline tumor,
and twomalignant ovarian tumors (one with low (+) and one with high
ARID3B staining (+++)) are shown (Figure 4A). Normal epithelia had
either little to no ARID3B (Figure 4B). Benign lesions (borderline se-
rous or mucinous papillary cystadenomas, and serous or mucinous cyst-
adenomas) had generally low staining, although 41% of the tissues had
either moderate (23%) or high (18%) staining (Figure 4B) indicating
heterogeneity of ARID3B expression in benign lesions. In contrast,
82% of malignant serous tumors (serous papillary cystadenocarcinomas
or adenocarcinomas) stained positive for ARID3B.Of these, 75% of the
tumors had moderate to high expression. There was an observed trend
of higher expression levels in both serous tumors and benign tumors
than in normal epithelium (P < .003). The expression level of ARID3B in
normal epithelium was significantly lower than serous tumors (P = .002).
The difference in ARID3B expression between benign tumors and nor-
mal epitheliumwas not statistically significant (P > .500).We have shown
that ARID3B is overexpressed in serous ovarian cancer and therefore may
contribute to cancer progression.
Discussion
We demonstrate that the EGFR pathway described inDrosophila lead-
ing to transcriptional repression of a miRNA through an ETS factor
is conserved in human ovarian tumor cells. Recently, it was shown that
miR-21, a tumor-promoting miRNA, is induced by EGFR in lung
cancer; however, the mechanism for this regulation is unknown [22].
Our data provide evidence for a novel mechanism of miRNA regulation
downstream of EGFR signaling. This is also the first example of EGFR-
mediatedmiRNA repression in human cells. Therefore, miRNA regula-
tion by growth factor signaling represents an additional way of regulating
tumor progression perhaps by fine-tuning oncogenic signaling.
Regulation of the mesenchymal-to-epithelial transition by miR-125a
represents the second example of a miRNA regulating this process. Re-
cently, it has been shown that the miR-200 family of miRNA correlates
with E-cadherin expression [23]. Forced expression ofmiR-200miRNA
induces a mesenchymal-to-epithelial transition in mesenchymal cells,
and inhibition of miR-200 induces EMT [23]. miR-125a regulation
of mesenchymal-to-epithelial transition seems to be through a different
mechanism because miR-125a does not regulate cadherin expression.
Alternatively, our data suggests that miR-125a regulates N-cadherin lo-
calization through an indirect mechanism. We predict that miR-125a
regulation of ARID3B contributes to the switch between mesenchymal
and epithelial morphologies.
Aberrant expression of miR-125a in ovarian cancer led to the identi-
fication of ARID3B as a target ofmiR-125a. ARID3B is required formes-
enchymal development in themouse [16], and we predict that miR-125a
repression of ARID3B plays a role in maintaining an epithelial mor-
phology. We propose a model in Figure 5 where EGFR signaling leads
to miR-125a transcriptional repression. The repression of miR-125a
releases ARID3B promoting a mesenchymal phenotype and contrib-
uting to disease progression.
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Figure W1. PEA3 expression in ovarian cancer cell lines. Western
blot analysis on OVCA433, 433mir125a, DOV13, and DOVmir125a
cells for PEA3 and β-tubulin. The 433mir125a and DOVmir125a
cells are cells overexpressing miR-125a.
Figure W2. Adherens junctions in OVCA433 cells overexpressing
miR-125a. Immunofluorescence performed for E-cadherin and
β-catenin on 433mir125a cells demonstrates the presence of
E-cadherin containing adherens junctions.
